Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

DB10994ApprovedWithdrawnVaccines

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen is one antigen component of a recombinant bivalent HPV vaccine. A component of a vaccine that protects against human papillomavirus (HPV), a virus that can cause cervical cancer.

First approval: United States, 2009

Resolves to

Compound

UNII7XB76X2V7T

What you can answer from here — as of April 02, 2025

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

12Marketed productsAcross 4 countries and 2 labellers

Which other approved drugs treat the same conditions as Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account